Takeda Chooses PRA To Lead Its Revamped Clinical Development Ops
Executive Summary
Takeda has chosen US-based PRA Health Sciences to lead its clinical development as part of the Japanese drug maker’s global R&D overhaul aimed at cutting costs and improving efficiency and innovation.
You may also be interested in...
Entyvio Takes Lead As Takeda Pursues Turnaround
Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.
Refocus, Optimize, Externalize: Takeda Overhauls Global R&D
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
Kinder cuts: CRO deals palliate pharma downsizing
Five years ago, pharma was in the throes of a vast cull as the global financial meltdown and the patent cliff combined to create a perfect storm for the industry. In 2009, more than 60,000 job cuts were announced in the sector in the US alone, according to the US outplacement specialist Challenger, Gray & Christmas.